close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Health Panel

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Health Profile

Enter health info to personalize results.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon
left-icon Back to Results

Dr. Bobby Liaw

LOCATION OF PRACTICE
Mount Sinai Health System
NPI Number
1851528731
ABOUT

Bobby Liaw, MD specializes in the care and management of patient’s with genitourinary and sarcoma cancers. He serves as the Clinical Director of Genitourinary Oncology for the Mount Sinai Health System, as well as the Medical Director for the Blavatnik Family Chelsea Medical Center at Mount Sinai.

Dr. Bobby Liaw profile image

Published Articles

Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma.- 2026 Feb 5
Effect of Chalcogen Ligands on the Redox Activity of Nickel Complexes for the Electrocatalytic Oxygen Evolution Reaction.- 2026 Jan
A Pilot Study of the Combination of 5-Azacitidine and All-trans Retinoic Acid in Biochemically Recurrent Prostate Cancer.- 2025 Aug 12
The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART).- 2024 Dec
Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy.- 2024 Oct 1
DR-70 (fibrinogen-fibrin degradation products) as a prognostic biomarker in dogs with neoplasms.- 2024 Dec
Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-targeted Therapy.- 2024 Jun 1
Structural Transformation in a Sulfurized Polymer Cathode to Enable Long-Life Rechargeable Lithium-Sulfur Batteries.- 2023 May 3
Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer.- 2023 Apr 6
First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis.- 2023 Jun

Clinical Trials

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider